U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07951346) titled 'N-Acetylcysteine as Adjuvant Therapy for Drug-Induced Hepatitis in Hospitalized Tuberculosis Patients' on Nov. 16.
Brief Summary: Anti-tuberculosis drug-induced liver injury (AT-DILI) is a common side effect of tuberculosis (TB) treatment. It often forces TB drugs to be stopped temporarily, which may reduce treatment success. N-acetylcysteine (NAC) is an antioxidant that helps the body make glutathione and may help the liver recover. Most previous studies tested NAC to prevent liver injury rather than to treat liver injury that has already occurred.
This study aimed to find out whether oral NAC, given as an adjuvant therapy, improv...